Osmolex ER FDA Approval History
Last updated by Judith Stewart, BPharm on March 2, 2021.
FDA Approved: Yes (First approved February 20, 2018)
Brand name: Osmolex ER
Generic name: amantadine hydrochloride
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceutical US LLC
Treatment for: Parkinson's Disease, Extrapyramidal Reaction
Osmolex ER (amantadine hydrochloride) is a proprietary formulation of immediate release and extended release amantadine for the once-a-day treatment of Parkinson’s disease and drug-induced extrapyramidal reactions.
Development timeline for Osmolex ER
|Feb 19, 2018||Approval FDA Approves Osmolex ER (amantadine) for the treatment of Parkinson’s Disease and Drug-Induced Extrapyramidal Reactions|
|Jul 22, 2015||Osmotica Announces OS-320 (Osmolex ER), Has Been Awarded Orphan Drug Status by the FDA|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.